Other

Merck Patent Gmbh

Hoechst Aktiengesellschaft

Centre National De La Recherche Scientifique

Genentech, Inc.

Merck Patent Gesellschaft MIT Beschrankter Haftung

Aventis Pharma S.a.

Laboratoire Theramex

Biokinesis

Hoechst Marion Roussel

Hoechst Japan Limited

Deinove

Sanofi-a Ventis Deutschland Gmbh

Aventis Pharma Deutschland, Gmbh

Merk Patent Gmbh

Denis Carniato

Thomas Gadek

Jochen Knolle

Robert S McDowell

Jean-Francois Gourvest

Sarah Catherine Bodary

Volkmar Wehner

Anuschirwan Peyman

Hans Ulrich Stilz

Jean-Marie Ruxer

Didier Roche

Christine G Charon

Jean-Michel Lefrancois

Anurschirwan Peyman

Cécile Bougeret

David William Will

Robert Maurice Pitti

Karl-Heinz Scheunemann

Robert Andrew Cuthbertson

Karlheinz Scheunemann

Liliane Doare

Caroline Leriche

Johannes Gleitz

Benoit Deprez

Catherine Guillou

Julien Rouleau

Julie Rivollier

Mathieu Gutmann

Olivier Busnel

Karine Jaillardon

Cecile Bougeret

Christine Charon

Hans-Jochen Lang

Jean-Georges Teutsch

Gerhard Breipohl

Jean-Claude Pascal

Bjoern Hock

Jean Lafay

Hans-Ulrich Stilz

Paule Bonnet

Masakazu Katoh

Amuschirwan Peyman

Tom Gadek

Serge Bernard

Ryoichi Satoh

Jean-Francois Briand

Norbert Beier

Hiroshi Kitagawa

Heinrich Christian Englert

Tsutomu Inoue

Gérard Moinet

Lars Thore Burgdorf

Ulrich Emde

Melanie Schultz

Sophie Hallakou-Bozec

Gérard Botton

Christoph Naumann

Franck F Lepifre

Francois Goubet

Eric Valeur

Mizuho Inazu

Anne-Marie Moura

Annick Audet

Nathalie Adje

Thierry Clerc

Dominique Le Beller

Remi Delansorne

Annick Arbellot De Vacqueur

Serge Christmann-Franck

Thomas R Gadek

Jacqueline Shields

Igor Duc

Eric Duranti

Napoleane Ferrara

Thomas Richard Gadek

Dominique Thomas

Fabien Schmidlin

Josef Aszodi

Benoît Deprez

Benoît Rondot

Guillaume Lesquame

Jean-François Briand

Marie-Helene Quernin

Franck Lepifre

Robert Mcdowell

Jean-François Gourvest

Caroline Lerich

The present invention relates to a new class of indole derivatives, having a particular MKlp2 inhibition profile and useful as a therapeutic agent, in particular for the treatment of cancer, viral infections and lung diseases.

Derivatives of indole for the treatment of cancer, viral infections and lung diseases

The invention relates to a new bicyclic lipolantipeptide, representing a new class of lantipeptide, and salts thereof, their preparation from a culture of a, and their use as antimicrobial agent in the prevention and treatment of infections in humans, animals or plants.

Bicyclic lipolantipeptide, preparation and use as antimicrobial agent

Piperazinyl derivatives of formula (I) and their use as a drug, particularly for the treatment of cancer, are disclosed. Also disclosed are pharmaceutical compositions comprising the piperazinyl derivatives, and methods for synthesizing the piperazinyl derivatives.

Piperazinyl derivatives for the treatment of cancer

The present invention relates to a new class of indole derivatives, having a particular MKlp2 inhibition profile and useful as a therapeutic agent, in particular for the treatment of cancer, viral infections and lung diseases. 

The present invention relates to piperazinyl derivatives of formula (I) and the use thereof as a drug, particularly for the treatment of cancer, the pharmaceutical compositions containing said derivatives, and the method for synthesising same. 

Imidazole derivatives of formula (I): wherein R, R, R, A, V and W are as defined in the description,

Imidazole derivatives as fructose-1,6-bisphosphatase inhibitors and pharmaceutical compositions containing them

The present invention relates to diazepane-acetamide derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11&#x3b2;-HSD-1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions. 

Diazepane acetamide derivatives as selective 11B-HSD1 inhibitors

The present invention relates to NIP thiazole derivatives of formula (I) as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11-&#x3b2;-HSD-1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions. 

NIP thiazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydroge-nase-1

The present invention relates to a compound of general formula (I): and also to the pharmaceutically acceptable salts thereof, to the isomers or isomer mixtures thereof in all proportions, in particular to an enantiomer mixture, and especially to a racemic mixture. The present invention also relates to the use of these compounds as a medicament, and in particular for the treatment of cancer, and also to the compositions containing them. 

Compounds which can be used for the treatment of cancers

The present invention relates to fused pyrrolidino-cyclopropane derivatives according to formulae (I) to (IV) as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11-&#x3b2;-HSD-1) and the use of such compounds for the treatment and/or prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.

Fused pyrrolidino-cyclopropane derivatives as selective 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors

The present invention relates to 7-azaindole derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11&#x3b2;-HSD-1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions. 

7-azaindole derivatives as selective 11-&#x3b2;-hydroxysteroid dehydrogenase type 1 inhibitors

The present invention relates to 2-adamantylurea derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11&#x3b2;-HSD1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions. 

2-adamantylurea derivatives as selective 11&#x3b2;-HSD1 inhibitors

Diazepane-acetamide derivatives as selective 11&#x3b2;-HSD1 inhibitors

Novel heterocyclic compounds of the formula I in which R, R, R, R, R, R, R, Alk and D have the meanings indicated in claimare activators of glucokinase and can be used for the prevention and/or treatment of Diabetes Typ 1 and 2, obesity, neuropathy and/or nephropathy.

N-(pyrazole-3-yl)-benzamide derivatives as glucokinase activators

Growing community of inventors

Marcoussis, France

Denis Carniato